353 related articles for article (PubMed ID: 24768356)
1. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
[TBL] [Abstract][Full Text] [Related]
4. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
6. Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser M; Sabelnykova VY; Yamaguchi TN; Heisler LE; Livingstone J; Huang V; Shiah YJ; Yousif F; Lin X; Masella AP; Fox NS; Xie M; Prokopec SD; Berlin A; Lalonde E; Ahmed M; Trudel D; Luo X; Beck TA; Meng A; Zhang J; D'Costa A; Denroche RE; Kong H; Espiritu SM; Chua ML; Wong A; Chong T; Sam M; Johns J; Timms L; Buchner NB; Orain M; Picard V; Hovington H; Murison A; Kron K; Harding NJ; P'ng C; Houlahan KE; Chu KC; Lo B; Nguyen F; Li CH; Sun RX; de Borja R; Cooper CI; Hopkins JF; Govind SK; Fung C; Waggott D; Green J; Haider S; Chan-Seng-Yue MA; Jung E; Wang Z; Bergeron A; Dal Pra A; Lacombe L; Collins CC; Sahinalp C; Lupien M; Fleshner NE; He HH; Fradet Y; Tetu B; van der Kwast T; McPherson JD; Bristow RG; Boutros PC
Nature; 2017 Jan; 541(7637):359-364. PubMed ID: 28068672
[TBL] [Abstract][Full Text] [Related]
7. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Gourdin T
Curr Opin Oncol; 2019 May; 31(3):188-193. PubMed ID: 30925537
[TBL] [Abstract][Full Text] [Related]
8. Prognostic outlier genes for enhanced prostate cancer treatment.
Kim H; Skowronski J; Den RB
Future Oncol; 2017 Feb; 13(3):249-261. PubMed ID: 27728977
[TBL] [Abstract][Full Text] [Related]
9. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.
Yadav SS; Li J; Lavery HJ; Yadav KK; Tewari AK
Urol Oncol; 2015 Jun; 33(6):267.e1-13. PubMed ID: 25791755
[TBL] [Abstract][Full Text] [Related]
11. Personalising Prostate Radiotherapy in the Era of Precision Medicine: A Review.
Spence W
J Med Imaging Radiat Sci; 2018 Dec; 49(4):376-382. PubMed ID: 30514554
[TBL] [Abstract][Full Text] [Related]
12. [Personalised medicine in prostate cancer].
Pfister D; Haidl F; Paffenholz P; Nestler T; Heidenreich A
Aktuelle Urol; 2019 Sep; 50(5):509-512. PubMed ID: 31466098
[TBL] [Abstract][Full Text] [Related]
13. Genomic Predictors of Outcome in Prostate Cancer.
Boström PJ; Bjartell AS; Catto JW; Eggener SE; Lilja H; Loeb S; Schalken J; Schlomm T; Cooperberg MR
Eur Urol; 2015 Dec; 68(6):1033-44. PubMed ID: 25913390
[TBL] [Abstract][Full Text] [Related]
14. Reprint of: The prostate cancer genome: Perspectives and potential.
Barbieri CE; Tomlins SA
Urol Oncol; 2015 Feb; 33(2):95-102. PubMed ID: 25726356
[TBL] [Abstract][Full Text] [Related]
15. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
Huang J; Wang JK; Sun Y
Curr Opin Urol; 2013 May; 23(3):189-93. PubMed ID: 23385974
[TBL] [Abstract][Full Text] [Related]
17. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
18. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
[TBL] [Abstract][Full Text] [Related]
19. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
20. Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
